Alison Ventura takes helm at Oysterponds Historical Society timesreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from timesreview.com Daily Mail and Mail on Sunday newspapers.
false narrative about the 2020 election results which the committee believes played a big role in bringing so many people to the capitol on january 6th and then you have the members of the counsel s office who were pushing back against that pressure campaign that was put on former vice president pence. this is all part of that big, wide net that the committee is casting to get as much information as possible to, you the final report we believe some time this fall. victor and alisyn? thank you for the update. thank you for staying with us. i m victor blackwell. and i m alisyn. the frontline is intensifying in the east. senior u.s. defense officials are seeing those russian troops who retreated from northern
Canadian Modern Slavery Bill Would Cast A Wide Net On Supply Chain Transparency Practices - Government, Public Sector mondaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondaq.com Daily Mail and Mail on Sunday newspapers.
Significant Progress Made as Numinus-Sponsored PRIME Study on Psilocybin-Assisted Psychotherapy for Opioid, Stimulant and/or Alcohol Use Disorders Enters Pre-Implementation Stage
Numinus Wellness (OTC:LKYSD) and Syreon Corporation, a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. The study will contribute to a growing body of research to inform larger randomized controlled trials for these indications. The study will take place in Vancouver and will enroll 30 individuals with opioid, stimulant and/or alcohol use disorders. Syreon is leading the trial as Clinical Research Organization (CRO) with Numinus as the trial sponsor.